US Patent

US11504375 — ErbB/BTK inhibitors

Method of Use · Assigned to Dizal Jiangsu Pharmaceutical Co Ltd · Expires 2039-01-28 · 13y remaining

Vulnerability score 75/100 Vulnerable — likely target for IPR or design-around

What this patent protects

This patent protects compounds that inhibit ErbB and BTK proteins, which can be used to treat diseases associated with these proteins, including cancer.

USPTO Abstract

Disclosed are compounds inhibiting ErbBs (e.g., EGFR or Her 2), especially mutant forms of ErbBs, and BTK, pharmaceutically acceptable salts, hydrates, solvates or stereoisomers thereof and pharmaceutical compositions comprising the compounds. The compound and the pharmaceutical composition can effectively treat ErbBs (especially mutant forms of ErbBs) or BTK associated diseases, including cancer.

Drugs covered by this patent

FDA Patent Use Codes

When a patent is method-of-use, FDA lists it once per applicable indication ("U-code"). Each U-code carves out a specific therapeutic use that generic filers must either license or design around.

Code	Description	Drug
`U-3220`	—
`U-3220`	—

Patent Metadata

Patent number: US11504375
Jurisdiction: US
Classification: Method of Use
Expires: 2039-01-28
Drug substance claim: Yes
Drug product claim: Yes
Assignee: Dizal Jiangsu Pharmaceutical Co Ltd
Source: FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.